Provided by Tiger Trade Technology Pte. Ltd.

NRX Pharmaceuticals Inc.

3.45
-0.1100-3.09%
Volume:898.03K
Turnover:3.15M
Market Cap:149.37M
PE:-4.45
High:3.61
Open:3.52
Low:3.44
Close:3.56
52wk High:5.06
52wk Low:1.62
Shares:43.30M
Float Shares:36.46M
Volume Ratio:1.04
T/O Rate:2.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7754
EPS(LYR):-1.3374
ROE:-682.61%
ROA:-63.99%
PB:-878.65
PE(LYR):-2.58

Loading ...

NRX Pharmaceuticals - Initiates Arbitration with Kadima over Failed Closing Conditions

THOMSON REUTERS
·
Jun 26

NRX Pharmaceuticals Responds to Recent Public Statements Regarding Kadima Dispute

THOMSON REUTERS
·
Jun 26

NRX Pharmaceuticals: Co Does not Believe That Acquisition/non-acquisition of Any Individual Clinic Would be Material to Hope's Overall Business Model

THOMSON REUTERS
·
Jun 26

H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP)

TIPRANKS
·
Jun 25

Nrx Subsidiary HOPE Therapeutics Begins Patient Treatments Using Zeta Surgical TMS Navigation System

Reuters
·
Jun 25

NRX Pharmaceuticals (nasdaq: Nrxp) Subsidiary Hope Therapeutics Treats First Patients Using Zeta Surgical's Fda-cleared Zeta Tms Navigation System

THOMSON REUTERS
·
Jun 25

Kadima Neuropsychiatry Institute alleges NRx breached contract

TIPRANKS
·
Jun 25

Kadima Neuropsychiatry Institute Files Suit Against NRX Pharmaceuticals (nasdaq: Nrxp), Alleging Breach of Contract and Misrepresentation in Connection with Acquisition

THOMSON REUTERS
·
Jun 25

Kadima Neuropsychiatry Institute: Lawsuit Seeks Specific Performance in Court Order Compelling Defendants to Close Deal on Terms in Executed Agreement

THOMSON REUTERS
·
Jun 25

Kadima Neuropsychiatry Institute: Complaint Alleges NRX Warranted it Had Funds to Close While Concealing it Lacked Committed Financing for Deal

THOMSON REUTERS
·
Jun 25

Kadima Neuropsychiatry Institute Sues Nrx Pharma over Alleged Breach, Misrepresentation in Acquisition Deal

Reuters
·
Jun 25

HOPE Therapeutics treats first patient using Zeta TMS Navigation System

Reuters
·
Jun 23

Zeta Surgical® Announces Successful Treatment of First Patient With Zeta Tms Navigation System at Hope Therapeutics

THOMSON REUTERS
·
Jun 23

Thomas Shrader Reiterates Buy on NRXP, Maintains $25 Price Target on NRX-100/101 FDA and RWE-Driven Upside

TIPRANKS
·
Jun 23

NRx Pharma says FDA grants expanded access protocol for NRX-101 depression treatment

Reuters
·
Jun 22

NRX Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-Based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of Depression

THOMSON REUTERS
·
Jun 22

NRX Pharmaceuticals - to Charge Only Shipping and Data Costs for NRX-101 Under Protocol

THOMSON REUTERS
·
Jun 22

NRX Pharmaceuticals - Initiates Pivotal Trial of NRX-101 for Tms Augmentation

THOMSON REUTERS
·
Jun 22

NRx notes real-world study showing IV ketamine beats nasal esketamine on depression remission, response rates

Reuters
·
Jun 05

NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.

GlobeNewswire
·
Jun 05